Janssen Inc. and Actelion Pharmaceuticals Ltd. have brought a patent infringement action against Apotex Inc. The plaintiffs allege that Apotex's generic medication, APO-MACITENTAN, will infringe their patent related to the combination of macitentan and a specific type of drug. Apotex defends the allegations, claiming that it will not directly or indirectly infringe the asserted claims. The court ruled that Apotex will not directly infringe the claims but will induce infringement of claims 1-5 and 21-31.

No uploaded documents